enclomifene citrate
- Generic Name
- enclomifene citrate
An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2015-03-12
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02274181
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01991327
A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01959685
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT01739582
Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 499
- Registration Number
- NCT01534208
- Locations
- 🇺🇸
IRC Clinics, Towson, Maryland, United States
🇺🇸Meridien Research, St. Petersburg, Florida, United States
🇺🇸Breco Research, Sugar Land, Texas, United States
Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT01532414
- Locations
- 🇺🇸
Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States
🇺🇸Coastal Clinical Research, Mobile, Alabama, United States
🇺🇸SC Clinical Research, Garden Grove, California, United States
Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism
- Conditions
- Secondary Hypogonadism
- Interventions
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT01270841
- Locations
- 🇺🇸
Paradigm Clinical Inc., Garden Grove, California, United States
🇺🇸Northern California Research Corp, Sacramento, California, United States
🇺🇸Jed Kaminetsky, New york, New York, United States
Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes MellitusSecondary Hypogonadism
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT01191320
- Locations
- 🇺🇸
LABioMed, Torrance, California, United States
🇺🇸Dr. Bruce Gilbert, Great Neck, New York, United States
🇺🇸TX Urology Associate, Houston, Texas, United States
Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism
- First Posted Date
- 2010-02-11
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT01067365
- Locations
- 🇺🇸
Office of Stephen Miller, MD, Las Vegas, Nevada, United States
🇺🇸Northern California Research Corp, Carmichael, California, United States
🇺🇸Harbor-UCLA Medical Center, Torrance, California, United States
Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism
- Conditions
- Secondary Hypogonadism
- Interventions
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2010-02-11
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT00962637
- Locations
- 🇺🇸
Northeast Indiana Research, LLC, Fort Wayne, Indiana, United States
🇺🇸Salt Lake Research, Salt Lake City, Utah, United States
🇺🇸Southeastern Research Group, Inc., Tallahassee, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.